Kansɛri min bɛ fogonfogon na, o bana kun ye mun ye?
Ka fara o kan, bana minnu bɛ sɔrɔ sumayabana de senfɛ, olu ka teli ka juguya.
Biɲɛdimi ye bana ye min bɛ sɔrɔ banakisɛw cayali ni u tilani fɛ.
Nin seliliw bɛ se ka sumuniw dilan ani ka jɛnsɛn fari fan wɛrɛw la, ka na ni taamasiɲɛw ni gɛlɛya caman ye.
Biɲɛdimi bɛ sɔrɔ fɛn caman fɛ, i n'a fɔ joli siraw yɛlɛmacogo, sigida lamini fɛn, ani ɲɛnamaya kɛcogo sugandili.
Genetiki yelemali be se ka sɔrɔ biɲɛ seliliw ka DNA kono, min be na ni seliliw ka cayali ni u tilani ye ka bɔ u cogoya kɔrɔ.
O joli yɛlɛmataw bɛ se ka sɔrɔ cɛya fɛ wala musoya fɛ, u sababu bɛ se ka kɛ fɛn dɔw ye i n'a fɔ sigarɛti sigarɛti, azetaminofɛni ani safinɛ.
Biɲɛdimi bɛ se ka kɛ bana suguya fila ye: bana min bɛ wele ko kansɛri min bɛ sɔrɔ banakisɛ fitiniw na (SCLC) ani bana min tɛ sɔrɔ banakisɛ fitiniw na (NSCLC).
Nin sɛrɛ suguya caman na biɲɛdimi bɛ se ka kɛ bana suguya kelen ye, barisa yɛlɛma suguya kelen don u la ani u bɛ furakɛ cogoya kelen.
Ka fara o kan, bana min bɛ sɔrɔ biɲɛdimi fɛ, o bɛ sɔrɔ kansɛribana fɛ.
Kansɛri seliliw bɛ se ka kisi farikolo tangacogo ma, o bɛ a to u bɛ bonya ani ka jɛnsɛn u yɛrɛ ma.
Ka fara o kan, tumumisɛnniw ka yɔrɔ bɛ se ka tumumisɛnniw ka bonya ni u ka yɛlɛma ka kɛ yɔrɔ wɛrɛw ye ka dɛmɛ don kansɛri bana kisɛw ma.
Biɲɛdimi ni kansɛri bana kuntaala bɛ yɛlɛma don ɲɔgɔn na, wa ɲinini kɛlaw bɛ baara kɛ tuma bɛɛ walasa ka a dɔn ka ɲɛ fura minnu ka ɲi ani ka banabagatɔw furakɛ ka ɲɛ.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Kunnafoni nafama: kɛnɛya']
['Nin gafe in labɛnna kalan ni kunnafoni dɔrɔn de kama, a tɛ sɔrɔ dɔgɔtɔrɔ ka ladili wala kɛnɛyabaarakɛla ka baara kɛcogo la.']
["Kunnafoni minnu dira aw ma, aw man kan ka olu kɛ ka banaw furakɛ. Mɔgɔ minnu b'u yɛrɛ furakɛ, olu ka kan ka dɔgɔtɔrɔ dɔ ka dɛmɛ ɲini."]
["Aw ye aw janto nin na: ɛntɛrinɛti min bɛ jabi di ɲininkaliw jaabiliw kan, o dabali ka jugu kɛrɛnkɛrɛnnenya la n'a bɛ tali kɛ jatidenw de kan. Misali la, mɔgɔ hakɛ min ka bana kofɔra."]
['Aw bɛ ladilikan ɲini tuma bɛɛ aw ka dɔgɔtɔrɔ fɛ walima kɛnɛya baarakɛla dɔ wɛrɛ min bɛ se ka aw dɛmɛ ka aw ka bana furakɛ. Aw kana dɔgɔtɔrɔ ka ladilikan bila ka suma walima ka mɛn a ɲini na sabu aw ye fɛn dɔ kalan nin siti kan. Ni aw hakili la ko aw ka bana bɛ se ka juguya joona, aw ye 911 wele walima aw ka taa aw ka dɔgɔtɔrɔso la joona joona. Nin siti tɛ dɔkɔtɔrɔ ni banabagatɔ ka jɛɲɔgɔnya jira. BioMedLib ni a ka baaradenw, walima nin siti dɛmɛbaga si tɛ kuma si jira walima ka jira, nin kunnafoniw wala u labaarali kama.']
['Kunnafoni min lakodɔnna:']
["Digital Millennium Copyright Act san 1998, 17 U.S.C. § 512 (a DMCA) bɛ sariya sigi ka ɲɛsin mɔgɔ ma min b'a miiri ko fɛn min bɛ sɔrɔ intɛrinɛti kan, o bɛ tɔɲɔ a ka sariyaw la Ameriki jamana ka sariya kɔnɔ. "]
['Ni i dara a la kô i ka site web ni a baara tchogow bè i ka lakananifènw la, i (walima i ka lasigiden) bè se ka i yèrè ka lakananifènw bila ka o site web ni a baara tchogow bila kènèkan.']
['Waajibi don kunnafoniw ci kɛtɔ ka kɛ sɛbɛn ye e-mail fɛ (e-mail de kan ka lajɛ sɛbɛn ɲɛ Kunnafoniw lajɛ yɔrɔ la).']
["DMCA bɛ a ɲini i ka kunnafoni sɛbɛn bɔlɔlɔw kan kojugukɛ sɛbɛn bɛ sɛbɛn min kɔnɔ, o ka kan ka nin kunnafoniw fara a kan: (1) sɛbɛnni kɛtɔ ka sɛbɛnni kɛ min bɛ sɛbɛnni kɛ ni a ma kɛ kojugukɛ sɛbɛn ye; (2) sɛbɛnni kɛtɔ ka fɛn kofɔlen in kofɔ ani kunnafoni minnu bɛ a to an bɛ se ka fɛn kofɔlen in sɔrɔ; (3) i ka ladɛrɛsi, i ka ladɛrɛsi, telefɔni nimɔrɔ ani i ka ladɛrɛsi; (4) i ka kumaɲɔgɔnya sɛbɛn ko i dalen b'a la ko i bɛ a dɔn ko i bɛ ka fɛn kofɔlen in kɛ ni sariya min ye, o ma di sɛbɛnnikɛbaga ma, a ka ladɛrɛsi tigi, walima sariya wɛrɛ; "]
['(5) a ka seereyasɛbɛ sɛbɛntiya, ko seereyasɛbɛ minɛnen bɛ kojugubakɛlaw kama, ko kunnafoni min bɛ o sɛbɛntiya kɔnɔ, ko tiɲɛ don ani ko i yamaruyalen don ka yamaruya di ka kɛwalew kɛ minnu bɛ tiɲɛni kɛ; ']
['ani (6) sɛbɛn dɔ ka boloci walima ɛkitɔrɔniki sɛbɛn sɛbɛn tigi fɛ walima mɔgɔ min yamaruyara ka baara kɛ sɛbɛn tigi tɔgɔla. ']
['Ni kunnafoni fɔlen ninnu bɛɛ ma fara ɲɔgɔn kan, o bɛ se ka kɛ sababu ye ka mɛn baara kɛli la i ka sɛbɛn kɔnɔ.']
['Ɲɔgɔnkunbɛn']
['Sɛbɛn ɲɛ Ɲiningaliw / ladiliw']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɲɔgɔn fɛ']
['BioMedLib bɛ baara kɛ ni ɔridinatɛri ye (mansin ka kalan aligoritimiw) walasa ka ɲininkaliw ni jaabiw di ɲɔgɔn ma.']
['An bɛ a daminɛ ni gafew miliyɔn 35 ye ka bɔ PubMed/Medline. Ani fana, ɛntɛrinɛti sitiw ka bɔ RefinedWeb.']
